开云网页登录_开云app官网入口下载苹果版

Abstract

CLC Number:

R593.26

References41

[1]	Lundberg IE, Fujimoto M, Vencosky J, et al. Idiopathic inflammatory myopathies[J]. Nat Rev Dis Primer, 2021, 7(1): 86. doi:10.1038/s41572-021-00321-x URL
[2]	Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7): 344-347. doi:10.1056/NEJM197502132920706 URL
[3]	Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts)[J]. N Engl J Med, 1975, 292(7): 403-407. doi:10.1056/NEJM197502202920807 URL
[4]	Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Ann Rheum Dis, 2017, 76(12): 1955-1964. doi:10.1136/annrheumdis-2017-211468pmid:29079590
[5]	Mammen AL, Allenbach Y, Stenzel W, et al. 239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018[J]. Neuromuscul Disord, 2020, 30(1): 70-92. doi:10.1016/j.nmd.2019.10.005 URL
[6]	de Souza FHC, Vilela VS, et al. Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies[J]. Adv Rheumatol, 2019, 59(1): 6. doi:10.1186/s42358-019-0048-x URL
[7]	Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists[J]. J Dermatol, 2019, 46(1): e1-e18. doi:10.1111/1346-8138.14604 URL
[8]	Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment[J]. J Am Acad Dermatol, 2020, 82(2):283-296. doi:S0190-9622(19)32308-4pmid:31279813
[9]	Kobayashi I, Akioka S, Kobayashi N, et al. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-update[J]. Mod Rheumatol, 2020, 30(3): 411-423. doi:10.1080/14397595.2020.1718866pmid:31955618
[10]	Oddis CV, Aggarwal R. Treatment in myositis[J]. Nat Rev Rheumatol, 2018, 14(5): 279-289. doi:10.1038/nrrheum.2018.42 URL
[11]	Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomized trial[J]. Lancet, 2016, 387(10019): 671-678. doi:10.1016/S0140-6736(15)01021-1 URL
[12]	US National Library of Medicine. Combined treatment of methotrexate+glucocorticoidsversusglucocorticoids alone in patients with PM and DM(prometheus)[EB/OL]. 2016. https://clinicaltrials.gov/ct2/show/NCT00651040.
[13]	Fujisawa T, Hozumi H, Kamiya Y, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD[J]. Respirology, 2021, 26(4):370-377.
[14]	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9):765-770.
[15]	Anh-Tu Hoa S, Hudson M. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies[J]. Semin Arthritis Rheum, 2017, 46(4): 488-508. doi:10.1016/j.semarthrit.2016.07.014 URL
[16]	Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis[J]. N Engl J Med, 1993, 329(27): 1993-2000. doi:10.1056/NEJM199312303292704 URL
[17]	Hoff LS, de Souza FHC, Miossi R, et al. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis[J]. Rheumatology (Oxford), 2021. [Epub ahead of print].
[18]	Danieli MG, Moretti R, Gambini S, et al. Open-label study on treatment with 20% subcutaneous IgG administration in polymyositis and dermatomyositis[J]. Clin Rheum-atol, 2014, 33(4): 531-536.
[19]	Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial[J]. Arthritis Rheum, 2013, 65(2): 314-324. doi:10.1002/art.37754 URL
[20]	Barsotti S, Cioffi E, Tripoli A, et al. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature[J]. Reumatismo, 2018, 70(2): 78-84. doi:10.4081/reumatismo.2018.1011pmid:29976041
[21]	Egeli BH, Ergun S, Cetin A, et al. Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study[J]. Clin Rheumatol, 2022, 41(1): 123-127. doi:10.1007/s10067-021-05871-9 URL
[22]	Xiong A, Yang G, Song Z, et al. Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series[J]. Ther Adv Neurol Disord, 2021, 14: 1756286421998918.
[23]	Boppana SH, Syed HA, Antwi-Amoabeng D, et al. Atorvastatin-induced necrotizing myopathy and its response to combination therapy[J]. Cureus, 2021, 13(1): e12957.
[24]	Ge Y, Li S, Tian X, et al. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy[J]. Clin Rheumatol, 2021, 40(6): 2311-2317. doi:10.1007/s10067-020-05530-5 URL
[25]	Cui BB, Tian YR, Ma XY, et al. Belimumab for immune-mediated necrotizing myopathy associated with anti-SRP antibodies[J]. Front Immunol, 2021, 12: 777502. doi:10.3389/fimmu.2021.777502 URL
[26]	Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis[J]. Brain, 2009, 132(6): 1536-1544. doi:10.1093/brain/awp104 URL
[27]	Patwardhan A, Spencer CH. Biologics in refractory idiopathic inflammatory myositis (IIM): what experience in juvenile vs adult myositis tells us about the use of biologics in pediatric IIM[J]. Modern Rheumatology, 2021, 31(5): 933-948. doi:10.1080/14397595.2021.1881027 URL
[28]	Schiffenbauer A, Garg M, Castro C, et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis[J]. Semin Arthr-itis Rheum, 2018, 47(6): 858-864.
[29]	Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-alpha therapies: a systematic literature review[J]. Sci World J, 2014:179180.
[30]	Tjärnlund A, Tang Q, Wick C, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase Ⅱb treatment delayed-start trial[J]. Ann Rheum Dis, 2018, 77(1): 55-62. doi:10.1136/annrheumdis-2017-211751pmid:28993346
[31]	Zhang X, Zhou S, Wu C, et al. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis[J]. Rheumatology (Oxford), 2021, 60(7): e227-e228.
[32]	Li S, Li W, Jiang W, et al. The efficacy of tocilizumab in the treatment of patients with refractory immune-mediated necrotizing myopathies[J]. Front Pharmacol, 2021, 12: 635654. doi:10.3389/fphar.2021.635654 URL
[33]	Zong M, Dorph C, Dastmalchi M, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up[J]. Ann Rheum Dis, 2014, 73(5): 913-920. doi:10.1136/annrheumdis-2012-202857pmid:23625983
[34]	Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type Ⅰ IFN signature in blood of dermatomyositis and polymyositis patients[J]. Ann Rheum Dis, 2014, 73(1): 256-262. doi:10.1136/annrheumdis-2012-202794 URL
[35]	Amato AA, Hanna MG, Machado PM, et al. Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT[J]. Neurology, 2021, 23, 96(12): e1595-e1607. doi:10.1212/WNL.0000000000011626 URL
[36]	Hanna MG, Badrising UA, Benveniste O, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial[J]. Lancet Neurol, 2019, 18(9): 834-844. doi:10.1016/S1474-4422(19)30200-5 URL
[37]	Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease[J]. N Engl J Med, 2019, 381(3): 291-293. doi:10.1056/NEJMc1900045 URL
[38]	Navarro-Navarro I, Jiménez-Gallo D, Rodríguez-Mateos ME, et al. Behandlung refraktärer anti-NXP2-und anti-TIF1γ-dermatomyositis mit tofacitinib[J]. J Dtsch Dermatol Ges, 2021, 19(3): 443-447. doi:10.1111/ddg.14276_gpmid:33709603
[39]	Hornung T, Janzen V, Heidgen FJ, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib[J]. N Engl J Med, 2014, 371(26): 2537-2538. doi:10.1056/NEJMc1412997 URL
[40]	Delvino P, Bartoletti A, Monti S, et al. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis[J]. Rheumatology(Oxford), 2020, 59(12): e125-e127.
[41]	Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease[J]. Nat Rev Rheumatol, 2017, 13(4): 234-243. doi:10.1038/nrrheum.2017.23pmid:28250461

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References41

Related Articles0

Recommended Articles

Metrics

Comments